Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanassios Argiris

Showing results (41-50 of 122) with videos related to

Pageof 13
Sort By:
Investigational New Drugs|October 3, 2007
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancerAthanassios Argiris, Sanjiv S Agarwala, Michalis V Karamouzis, et al.
Cancer Treatment Reviews|July 22, 2022
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approachesIoannis A Vathiotis, Jennifer M Johnson, Adam Luginbuhl, et al.
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Cancer|November 26, 2009
The impact of health insurance status on the survival of patients with head and neck cancerJoseph Kwok, Scott M Langevin, Athanassios Argiris, et al.
Cancer Medicine|October 11, 2020
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)Laura B Oswald, Ju-Whei Lee, Athanassios Argiris, et al.
Frontiers in Oncology|May 25, 2017
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckAthanassios Argiris, Kevin J Harrington, Makoto Tahara, et al.
Cancer Immunology Research|April 15, 2017
Increased PD-1<sup>+</sup> and TIM-3<sup>+</sup> TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer PatientsHyun-Bae Jie, Raghvendra M Srivastava, Athanassios Argiris, et al.
Cancer|July 28, 2009
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology GroupAthanassios Argiris, Ashley Buchanan, Bruce Brockstein, et al.
The Laryngoscope|February 17, 2006
Planned post-chemoradiation neck dissection: significance of radiation doseKerstin M Stenson, Dezheng Huo, Elizabeth Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2010
Phase II study of everolimus (RAD001) in previously treated small cell lung cancerAhmad Tarhini, Athanasios Kotsakis, William Gooding, et al.
Pageof 13

Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Investigational New Drugs|October 3, 2007
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancerAthanassios Argiris, Sanjiv S Agarwala, Michalis V Karamouzis, et al.
Cancer Treatment Reviews|July 22, 2022
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approachesIoannis A Vathiotis, Jennifer M Johnson, Adam Luginbuhl, et al.
Cancer|January 20, 2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)Athanassios Argiris, Musie Ghebremichael, Barbara Burtness, et al.
Cancer|November 26, 2009
The impact of health insurance status on the survival of patients with head and neck cancerJoseph Kwok, Scott M Langevin, Athanassios Argiris, et al.
Cancer Medicine|October 11, 2020
Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)Laura B Oswald, Ju-Whei Lee, Athanassios Argiris, et al.
Frontiers in Oncology|May 25, 2017
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckAthanassios Argiris, Kevin J Harrington, Makoto Tahara, et al.
Cancer Immunology Research|April 15, 2017
Increased PD-1<sup>+</sup> and TIM-3<sup>+</sup> TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer PatientsHyun-Bae Jie, Raghvendra M Srivastava, Athanassios Argiris, et al.
Cancer|July 28, 2009
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology GroupAthanassios Argiris, Ashley Buchanan, Bruce Brockstein, et al.
The Laryngoscope|February 17, 2006
Planned post-chemoradiation neck dissection: significance of radiation doseKerstin M Stenson, Dezheng Huo, Elizabeth Blair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2010
Phase II study of everolimus (RAD001) in previously treated small cell lung cancerAhmad Tarhini, Athanasios Kotsakis, William Gooding, et al.
Pageof 13